DK2605655T3 - METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS - Google Patents
METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS Download PDFInfo
- Publication number
- DK2605655T3 DK2605655T3 DK11818848.1T DK11818848T DK2605655T3 DK 2605655 T3 DK2605655 T3 DK 2605655T3 DK 11818848 T DK11818848 T DK 11818848T DK 2605655 T3 DK2605655 T3 DK 2605655T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- disease
- mammal
- alzheimer
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40190710P | 2010-08-19 | 2010-08-19 | |
| PCT/US2011/048472 WO2012024616A1 (en) | 2010-08-19 | 2011-08-19 | Methods of treating miild cognitive impairment (mci) and related discorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2605655T3 true DK2605655T3 (en) | 2019-02-04 |
Family
ID=45605447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11818848.1T DK2605655T3 (en) | 2010-08-19 | 2011-08-19 | METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10449177B2 (enExample) |
| EP (1) | EP2605655B1 (enExample) |
| JP (2) | JP6250394B2 (enExample) |
| AU (1) | AU2011291506B2 (enExample) |
| BR (1) | BR112013003847A8 (enExample) |
| CA (1) | CA2808630A1 (enExample) |
| DK (1) | DK2605655T3 (enExample) |
| ES (1) | ES2705027T3 (enExample) |
| MX (1) | MX353096B (enExample) |
| WO (1) | WO2012024616A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2808630A1 (en) | 2010-08-19 | 2012-02-23 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| JP2015524477A (ja) | 2012-08-07 | 2015-08-24 | バック・インスティテュート・フォー・リサーチ・オン・エイジング | 神経機能を改善するための多成分製剤 |
| US10202355B2 (en) | 2013-02-12 | 2019-02-12 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| PT3119911T (pt) | 2014-03-21 | 2023-11-03 | Alzheon Inc | Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+ |
| WO2016134042A2 (en) | 2015-02-18 | 2016-08-25 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| WO2016187339A1 (en) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOIDß |
| HRP20230809T1 (hr) * | 2015-09-10 | 2023-10-27 | Alzheon, Inc. | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika |
| WO2017100623A1 (en) | 2015-12-09 | 2017-06-15 | Brandeis University | Dbh inhibitors for treating or preventing memory loss |
| US20180250249A1 (en) * | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
| IL262957B2 (en) | 2016-05-12 | 2024-04-01 | Buck Inst Res Aging | 6-Fluorotropistrone and a pharmaceutical formulation comprising it for the relief of amyloid-related diseases |
| US20210230221A1 (en) | 2017-01-03 | 2021-07-29 | Bioatla, Llc | Protein therapeutics for treatment of senescent cells |
| SG11202012099VA (en) | 2018-07-11 | 2021-01-28 | Rubedo Life Sciences Inc | Senolytic compositions and uses thereof |
| CN110232679A (zh) * | 2019-05-24 | 2019-09-13 | 潘丹 | 一种阿尔茨海默症遗传生物标志物确定方法及系统 |
| JP7618230B2 (ja) | 2019-07-25 | 2025-01-21 | 学校法人東京理科大学 | 精神・神経系の疾患又は症状を治療し、予防し又は改善する剤 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
| AU646877B2 (en) | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| JP3510244B2 (ja) | 1991-01-21 | 2004-03-22 | エラン ファーマシューティカルス，インコーポレイテッド | アルツハイマー病に関するテストおよびモデル |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5206264A (en) | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
| ATE243746T1 (de) | 1992-01-07 | 2003-07-15 | Elan Pharm Inc | Transgene tiermodelle fur alzheimer-krankheit |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| JPH09507746A (ja) | 1993-10-27 | 1997-08-12 | アテナ ニューロサイエンシズ，インコーポレイティド | Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物 |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| AU5002399A (en) | 1998-07-17 | 2000-02-07 | National Broach And Machine Company | Full form roll finishing technique |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| KR20070013361A (ko) | 1998-09-24 | 2007-01-30 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알츠하이머병 세크레타제 |
| US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| CA2369591C (en) | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
| US20040092511A1 (en) | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| US20070059367A1 (en) | 2000-06-06 | 2007-03-15 | Cherukuri S R | Drug Delivery System and Associated Methods |
| US20020115727A1 (en) | 2000-12-04 | 2002-08-22 | Senanayake Chris H. | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| US20020107244A1 (en) | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| CA2503381A1 (en) | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| US20040132826A1 (en) | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| FR2846559B1 (fr) | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| WO2005082887A1 (ja) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | ピリミジン誘導体 |
| AU2005235162B2 (en) | 2004-04-21 | 2010-11-18 | Mear Holding B.V. | System for measuring pulsatile vascular resistance |
| EP1741430B1 (en) | 2004-04-30 | 2009-07-15 | National University Corporation Chiba University | Remedy for psychoneurotic diseases |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| CN101132777A (zh) | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| ATE456552T1 (de) | 2004-12-23 | 2010-02-15 | Xenoport Inc | Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon |
| JP2008537887A (ja) | 2005-04-15 | 2008-10-02 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | アスコルベート結合ペプチド |
| GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| JP2009513672A (ja) * | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| CA2644458A1 (en) | 2006-03-01 | 2007-09-07 | Galderma Research & Development | Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof |
| CA2670418A1 (en) | 2006-11-24 | 2008-05-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's |
| WO2008074896A1 (en) | 2006-12-21 | 2008-06-26 | Prendergast Patrick T | Compositions and methods for treatment of chronic neurological disorders |
| WO2008137420A1 (en) | 2007-05-03 | 2008-11-13 | Emory University | Honokiol analogs and their use in treating cancers |
| US20090163451A1 (en) | 2007-11-16 | 2009-06-25 | Frank Porreca | Methods for treating visceral pain |
| CL2007003877A1 (es) | 2007-12-28 | 2008-06-27 | Univ De Concepcion Lab Androma | Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina. |
| CN103550847A (zh) | 2008-04-28 | 2014-02-05 | 佐吉尼克斯股份有限公司 | 用于治疗偏头痛的新制剂 |
| US8124600B2 (en) | 2008-05-29 | 2012-02-28 | Albany Molecular Research, Inc. | 5-HT3 receptor modulators, methods of making, and use thereof |
| US8604087B2 (en) | 2008-09-25 | 2013-12-10 | Bioland Ltd. | Composition for treating or preventing amyloid-related diseases comprising 4-O-methylhonokiol |
| US9622977B2 (en) | 2008-10-08 | 2017-04-18 | Bioplus Life Sciences Pvt, Ltd. | Sustained release drug delivery system |
| US20100099701A1 (en) | 2008-10-20 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Isoquinolinone modulators of 5-ht3 receptors |
| CN101444508B (zh) | 2008-12-29 | 2010-10-27 | 海南瑞基药物研究有限公司 | 一种注射用托烷司琼制剂及其制备方法 |
| CN102427782A (zh) | 2009-05-21 | 2012-04-25 | 比奥内克斯制药有限公司 | 双层和单层剂型 |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| US9790109B2 (en) * | 2010-04-30 | 2017-10-17 | General Electric Company | Method for sanitizing an electrodeionization device |
| CA2808630A1 (en) | 2010-08-19 | 2012-02-23 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| KR101368587B1 (ko) | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| WO2013123426A1 (en) | 2012-02-18 | 2013-08-22 | Buck Institute For Research On Aging | Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions |
-
2011
- 2011-08-19 CA CA2808630A patent/CA2808630A1/en not_active Abandoned
- 2011-08-19 BR BR112013003847A patent/BR112013003847A8/pt not_active IP Right Cessation
- 2011-08-19 EP EP11818848.1A patent/EP2605655B1/en active Active
- 2011-08-19 US US13/213,960 patent/US10449177B2/en active Active
- 2011-08-19 WO PCT/US2011/048472 patent/WO2012024616A1/en not_active Ceased
- 2011-08-19 ES ES11818848T patent/ES2705027T3/es active Active
- 2011-08-19 AU AU2011291506A patent/AU2011291506B2/en not_active Ceased
- 2011-08-19 MX MX2013001917A patent/MX353096B/es active IP Right Grant
- 2011-08-19 JP JP2013525003A patent/JP6250394B2/ja active Active
- 2011-08-19 DK DK11818848.1T patent/DK2605655T3/en active
-
2016
- 2016-08-18 JP JP2016160482A patent/JP2016193944A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016193944A (ja) | 2016-11-17 |
| JP2013534256A (ja) | 2013-09-02 |
| CA2808630A1 (en) | 2012-02-23 |
| BR112013003847A8 (pt) | 2017-12-26 |
| WO2012024616A1 (en) | 2012-02-23 |
| BR112013003847A2 (pt) | 2016-05-31 |
| US10449177B2 (en) | 2019-10-22 |
| US20120071468A1 (en) | 2012-03-22 |
| EP2605655A1 (en) | 2013-06-26 |
| ES2705027T3 (es) | 2019-03-21 |
| JP6250394B2 (ja) | 2017-12-20 |
| EP2605655B1 (en) | 2018-10-24 |
| MX353096B (es) | 2017-12-19 |
| AU2011291506B2 (en) | 2016-07-28 |
| MX2013001917A (es) | 2013-10-25 |
| EP2605655A4 (en) | 2014-01-08 |
| AU2011291506A1 (en) | 2013-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2605655T3 (en) | METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS | |
| CA2867891C (en) | App specific bace inhibitors (asbis) and uses thereof | |
| CA2899938C (en) | Hydantoins that modulate bace-mediated app processing | |
| EP2814491A1 (en) | Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions | |
| AU2017264931B2 (en) | Compounds to promote normal processing of APP | |
| EP3510029B1 (en) | Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition | |
| US20130102538A1 (en) | Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity | |
| US20170226059A1 (en) | Apoe4-targeted theraputics that increase sirt1 | |
| WO2025095099A1 (ja) | 前頭側頭葉変性症治療剤及び治療用組成物 | |
| JP2015514742A (ja) | β−アミロイドにより誘発された毒性と関連する疾患の治療における、３−（１’−アダマンチル）−１−アミノメチル−３，４−ジヒドロ−５，６−ジヒドロキシ−１Ｈ−２−ベンゾピランの使用 |